Trial · NCT01157091
Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer
NCT01157091, Phase 2, Completed, City of Hope Medical Center; results first posted 2022-04-05
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer. Trials, record NCT01157091. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01157091
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer
- NCT number
- NCT01157091
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 28 participants, actual
- Lead sponsor
- City of Hope Medical Center
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
- Interventions
- pazopanib hydrochloride, laboratory biomarker analysis, immunologic technique
- First posted
- 2010-07-05
- Last updated
- 2022-06-08
- Results first posted
- 2022-04-05
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Confirmed Response Rate (Complete Response and Partial Response) as Assessed by RECIST 1.1 Criteria | 1 year post treatment | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD; Overall Response (OR) = CR + PR. |
| Secondary | Progression-free Survival | 1 year post treatment | Kaplan-meier estimate of Progression-free survival, one-year post enrollment in the study. 95% Confidence Intervals are constructed using the Greenwood estimate of variance and log-log transformation. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or an unequivocal measured increase in a non-target lesion, or the appearance of new lesions |
| Secondary | Overall Survival | 1 year post treatment | One-year Kaplan-Meier estimate of survival, given in percent, with a 95% Confidence Interval based on the Greenwood variance, with log-log transform. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Confirmed Response Rate (Complete Response and Partial Response) as Assessed by RECIST 1.1 Criteria | 1 year post treatment | Participants with evaluable results. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Progression-free Survival | 1 year post treatment | percentage of participants | NUMBER | |
| SECONDARY | Overall Survival | 1 year post treatment | Patients eligible and enrolled | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group5
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Confirmed Response Rate (Complete Response and Partial Response) as Assessed by RECIST 1.1 Criteria | Arm I | Complete or Partial Response | 14 | Participants | |
| Confirmed Response Rate (Complete Response and Partial Response) as Assessed by RECIST 1.1 Criteria | Arm I | Stable | 7 | Participants | |
| Confirmed Response Rate (Complete Response and Partial Response) as Assessed by RECIST 1.1 Criteria | Arm I | Progression | 4 | Participants | |
| Progression-free Survival | Arm I | 70.0 | 95% Confidence Interval 48.7 to 83.8 | percentage of participants | |
| Overall Survival | Arm I | 96.0 | 95% Confidence Interval 72.9 to 99.4 | percentage of participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Oral Pazopanib HCl | 28 | |
| Overall Study | COMPLETED | Oral Pazopanib HCl | 28 | |
| Overall Study | NOT COMPLETED | Oral Pazopanib HCl | 0 |
Source ClinicalTrials.gov
Adverse events143
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | 10002272-Anemia | Blood and lymphatic system disorders | Arm I | 11 | 28 | 11 |
| other | 10033557-Palpitations | Cardiac disorders | Arm I | 1 | 28 | 1 |
| other | 10034474-Pericardial effusion | Cardiac disorders | Arm I | 1 | 28 | 1 |
| other | 10040741-Sinus bradycardia | Cardiac disorders | Arm I | 4 | 28 | 4 |
| other | 10040752-Sinus tachycardia | Cardiac disorders | Arm I | 7 | 28 | 7 |
| other | aortic sclerosis w/o significant stenosis, mitral annular calcification | Cardiac disorders | Arm I | 1 | 28 | 1 |
| other | 10005886-Blurred vision | Eye disorders | Arm I | 1 | 28 | 1 |
| other | 10000081-Abdominal pain | Gastrointestinal disorders | Arm I | 7 | 28 | 7 |
| other | 10002167-Anal pain | Gastrointestinal disorders | Arm I | 1 | 28 | 1 |
| other | 10005265-Bloating | Gastrointestinal disorders | Arm I | 1 | 28 | 1 |
1 to 10 of 143Source ClinicalTrials.gov
See all 143 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Arm I | 5 | 28 |
| Total, other adverse events | Arm I | 28 | 28 |
| Total, serious adverse events | Arm I | 8 | 28 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01157091
GET https://conductscience.org/api/trials/v1/NCT01157091/events?page=2